![Kenneth Hillan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Hillan
Director/Board Member at
SANGAMO THERAPEUTICS, INC.
Net worth: 21 713 $ as of 2026-05-30
Profile
Kenneth J.
Hillan is currently an Independent Director at Sangamo Therapeutics, Inc. since 2020 and a Director at Zymeworks BC, Inc. since 2017.
Formerly, Dr. Hillan was CEO, Director & President-R&D Division at Achaogen, Inc. from 2017 to 2019; Independent Director at Relypsa, Inc. from 2015 to 2016; Independent Director at Zymeworks, Inc. from 2017 to 2024; SVP & Head-Roche Product Development, Asia Pacific at Genentech, Inc. from 2010 to 2011; Member of Roche Group from 1994 to 2011; Head-Therapeutics at 23andMe, Inc. from 2019 to 2021; and Chief Therapeutics Officer at Chrome Holding Co. from 2022 to 2023.
Dr. Hillan earned a doctorate from the University of Glasgow School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-06-11 | 99,600 ( 0.02% ) | 21 713 $ | 2026-05-30 |
Kenneth Hillan active positions
| Companies | Position | Start |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Director/Board Member | 2020-09-10 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Director/Board Member | 2017-02-02 |
Former positions of Kenneth Hillan
| Companies | Position | End |
|---|---|---|
| ZYMEWORKS INC. | Director/Board Member | 2024-02-07 |
| CHROME HOLDING CO. | Corporate Officer/Principal | 2023-08-07 |
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Corporate Officer/Principal | 2021-05-31 |
| ACHAOGEN | Chief Executive Officer | 2019-04-03 |
| RELYPSA INC | Director/Board Member | 2016-08-31 |
Training of Kenneth Hillan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
87
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops non-absorbed polymeric drugs for applications in cardiovascular and renal diseases | Health Technology |
University of Glasgow School of Medicine
 University of Glasgow School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
23andMe Holding Co.
 23andMe Holding Co. BiotechnologyHealth Technology Operates as a genetic testing company | Health Technology |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
- Stock Market
- Insiders
- Kenneth Hillan
